Hemorrhagic shock secondary to portal hypertensive duodenopathy complicated by lupus and autoimmune liver cirrhosis

Samer Alkhuja, Jonathan Goldner

Department of Medicine, The Commonwealth Medical College, Pocono Medical Center, East Stroudsburg

Email address: alkuja@yahoo.com(S. Alkhuja), jgoldner@pmchealthsystem.org(J. Goldner)


Abstract: Systemic lupus erythematosus is a common autoimmune disorder that frequently is complicated by additional autoimmune diseases. There is a correspondence between hepatic diseases and systemic lupus erythematosus that ranges from subclinical elevations of liver enzymes to hepatic infarction. We present a rare case of portal hypertensive duodenopathy in a patient with autoimmune hepatitis/liver cirrhosis associated with systemic lupus erythematosus. Patients with systemic lupus erythematosus who present with upper gastrointestinal bleed should be evaluated for abnormal liver functions and have portal hypertensive duodenopathy included in the differential diagnosis.

Keywords: Shock, Lupus, Liver Cirrhosis, GI Bleed

1. Case Presentation

A 42 year old women presented to the emergency department (ED) with dizziness, nausea and having melena for one day. She has a past medical history of systemic lupus erythematosus (SLE), gastric esophageal reflux disease, cholelithiasis, chronic anemia, asthma, biopsy proven autoimmune hepatitis (AIH), and liver cirrhosis. Her past surgical history includes an esophagogastroduodenoscopy (EGD), which was normal, and a liver biopsy two years ago. Test for antinuclear antibodies was positive.

Her home medications include prednisone, azathipriprine, lansoprazole, hydroxycloroquine and albuterol. The patient is a smoker of 6-7 cigarettes/day. She denied alcohol consumption or allergies. Her family history was significant for diabetes mellitus, hypertension, and hypercholestremia. Physical examination, in the ED, revealed blood pressure (BP) 77/49 mmHg, pulse 132/minute, respiration 22/minutes, temperature 37.5° Celsius. The reminder of her examination was unremarkable. Blood pressure improved with intravenous (IV) fluids and blood transfusion, with subsequent systolic BP measurements in the 90s mmHg.

Laboratory findings were: Complete blood count showed white blood cell 8,000 (normal range 4200 – 10,200), hemoglobin 7.0 g/dL (normal range 12-15), hematocrit 20.8% (normal range 37-47%), platelet 99,000 (normal range 140,000 – 450,000). Prothrombin time was 19 seconds (normal range 9.0 – 12.0) Activated partial thromboplastin time was 41 seconds (normal range 24 – 36), and International normalized ration 1.8 (normal range 0.9 – 1.1). AST 131 IU/L (normal range 15-41), ALT 81 IU/L (normal range 17 -68), total bilirubin 0.9 mg/dL (normal range 0.3 – 1.2), direct bilirubin 0.3 mg/dL (normal range 0.1-0.5), alkaline phosphatase 48 IU/L (normal range 38 – 126), albumin 1.6 g/dL (normal range 3.5 – 5.0), amylase 61 IU/L (normal range 28 – 100), lipase 20 IU/L (normal range 22 – 51), and alpha-fetoprotein 1.8 ng/ml (normal range 0.5-9.0).

Electrocardiogram showed sinus tachycardia. Computed tomography (CT) scan of abdomen and pelvis showed the spleen measuring 9.3 cm, gallbladder demonstrates calculi, liver showed nodular contour suggesting cirrhosis. Chest radiograph showed blunting of the right costophrenic angle.

While in the intensive care unit, despite treatment with IV fluid and blood transfusions, the patient’s BP measurements were in the 70s mmHg. Intubation was performed for airway protection in view of hemodynamic instability secondary to hemorrhagic shock, and lethargy which was followed by unresponsiveness. An EGD was performed and demonstrated normal findings on inspection of esophagus and stomach. Examination of second and
third portion of the duodenum showed an actively bleeding duodenal varix (DV). Lavage was performed and injection of 6 mL of ethamolin 5% into the DV for temporary homeostasis was performed. The patient was kept intubated until the achievement of hemodynamic satbility, and immediately underwent placement of transjugular intrahepatic portosystemic shunts which resulted in permanent homeostasis and resolving of hemorrhagic shock, and shortly after was extubated. The patient was discharged home six days after presentation.

2. Discussion

SLE is a common autoimmune disorder characterized by multisystem involvements and complicated by other autoimmune disease. Hepatic involvement in patients with SLE has been reported. Elevated levels of transaminases associated with SLE was reported in 1/3 of patients reportedly by Miller et al. (1), and in 19 (23.5%) of 81 patients reported by Gibson et al. (2).

In a review of 40 patients with liver enzymes abnormalities and SLE, 6 were found to have AIH and 3 had cirrhosis (3). Runyon et al. reported only four (1.7%) of 238 patients with SLE to have AIH or cirrhosis (4). A review by Mastsumoto et al. autopsy registry data for 1,468 patients with SLE indicates that the incidence of chronic liver disease in SLE autopsy is AIH, 2.4%; cirrhosis, 1.1%; and liver fibrosis, 0.8% (5). AIH complicated by SLE should be considered not as a part of the range of AIH, but rather as a category of AIH-SLE overlap (6).

Gastrointestinal (GI) manifestations of SLE were reviewed by Xu et al., and were found in 39 (22%) of 177 consecutive SLE patients (7). GI complications occurred as the initial symptoms in 12 patients (12/39). Four patients (10.3%) in the group with GI complications died. While the mortality rate in SLE without GI complications was only 2.2%, this suggests that SLE patients with GI manifestations have worse prognosis than those without (7).

Portal hypertensive duodenopathy (PHD) is rare and was found only in 46 (8.4%) of 549 patients with cirrhosis and portal hypertension who underwent EGD (8). Mastusi et al. documented in a review of 12 patients with endoscopically DVs their underlying disease consisted of liver cirrhosis in 8 patients, and pancreatic cancer-related pylephremaxis in 4 patients (8). DVs are uncommon and account only for 5% of variceal hemorrhages (9), they often have a fatal outcome with a mortality as high as 40% (9). Verbeeck et al. reported successful temporizing treatment by precutaneous transhepatic embolization (9). Okahara et al. reported successful treatment of DVs by retrograde transvenous obliteration with additional or alternative techniques as a result of the complex hemodynamic features of the DVs (10).

3. Conclusion

PHD although rare but it may present as hemorrhagic shock as a result of upper GI bleed secondary to DV in a patient with AIH/liver cirrhosis. PHD should be considered in the differential diagnosis of an SLE patient with liver cirrhosis who is presenting with an upper GI bleed.

References